Belief in the value of DNA sequence led to investment in the technology that made the Human Genome Project possible. But DNA sequences are not in themselves inventions, and gene variants and the conditions in which they cause disease are discovered and held by many stakeholders. So, if patents are to continue to provide incentives of benefit from genomics, they must be licensed for competition that is not a zero-sum game.